×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北... [72]
复旦大学上海医学院 [29]
吉林大学白求恩第一... [13]
西安交通大学 [11]
合肥物质科学研究院 [11]
四川大学 [9]
更多...
内容类型
期刊论文 [133]
会议论文 [44]
发表日期
2023 [1]
2022 [5]
2021 [4]
2020 [1]
2019 [16]
2018 [38]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共177条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
期刊论文
BLOOD ADVANCES, 2023, 卷号: 7
作者:
Bachy, Emmanuel
;
Savage, Kerry J.
;
Huang, Huiqiang
;
Kwong, Yok-Lam
;
Gritti, Giuseppe
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2023/11/10
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Bachy, Emmanuel
;
Savage, Kerry J.
;
Huang, Huiqiang
;
Kwong, Yok-Lam
;
Gritti, Giuseppe
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
The Prognostic Utility of F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients
期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:
Li, Cong
;
Yu, Haifeng
;
Chen, Xi
;
Han, Shuiyun
;
Peng, Shuailing
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2022/12/23
diffuse large B cell lymphoma (DLBCL)
interim 18 F-FDG PET
prognosis
RCHOP
treatment response
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
期刊论文
BLOOD ADVANCES, 2022, 卷号: 6
作者:
Yang, Haiyan
;
Xiang, Bing
;
Song, Yuqin
;
Zhang, Huilai
;
Zhao, Weili
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2022/12/23
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:
Song, Yuqin
;
Gao, Quanli
;
Zhang, Huilai
;
Fan, Lei
;
Zhou, Jianfeng
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2022/05/05
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
期刊论文
BMC CANCER, 2022, 卷号: 22
作者:
Chen, Xi
;
Kong, Haiying
;
Luo, Linxiang
;
Han, Shuiyun
;
Lei, Tao
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2022/02/14
Hodgkin lymphoma
PD-1 inhibitor
PD-L1 inhibitor
PD-L2
Molecular phenotype
Tumor microenvironment
Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
期刊论文
BLOOD, 2021, 卷号: 138
作者:
Ding, Kaiyang
;
Liu, Hailing
;
Yang, Haiyan
;
Cao, Lei
;
Zhao, Xiaoli
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2022/12/23
The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
期刊论文
BLOOD, 2021, 卷号: 138
作者:
Ding, Kaiyang
;
Shi, Xiao
;
Yang, Haiyan
;
Cao, Lei
;
Zhao, Xiaoli
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2022/12/23
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9
作者:
Zhou, Yu-bo
;
Zhang, Yang-ming
;
Huang, Hong-hui
;
Shen, Li-jing
;
Han, Xiao-feng
收藏
  |  
浏览/下载:93/0
  |  
提交时间:2021/11/04
multiple myeloma
HDAC inhibitor
bisthianostat
pharmacodynamics
pharmacokinetics
phase 1a clinical trial
antitumor drug
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:
Song, Yuqin
;
Gao, Quanli
;
Zhang, Huilai
;
Fan, Lei
;
Zhou, Jianfeng
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2022/01/10
©版权所有 ©2017 CSpace - Powered by
CSpace